Workflow
华纳药厂(688799) - 2024 Q4 - 年度业绩
688799HWPC(688799)2025-02-26 08:25

Financial Performance - In 2024, the company achieved total operating revenue of 1.41 billion yuan, a decrease of 1.38% compared to the previous year[6] - The net profit attributable to the parent company was 172.37 million yuan, down 18.43% year-on-year[6] - In Q4 2024, the company reported operating revenue of 344 million yuan, a year-on-year decline of 8.86%[7] - The net profit attributable to the parent company in Q4 2024 was 14 million yuan, down 73.68% year-on-year[7] - The basic earnings per share for the year were 1.84 yuan, a decrease of 18.22% compared to the previous year[3] - The weighted average return on net assets decreased to 9.60%, down 2.92 percentage points from the previous year[3] Research and Development - R&D expenses increased significantly to 158.33 million yuan, reflecting a growth of 53.45% compared to the previous year, driven by ongoing new product development[8] Assets and Equity - Total assets at the end of the reporting period reached 2.47 billion yuan, representing a year-on-year increase of 13.36%[6] - The equity attributable to the parent company was 1.81 billion yuan, up 5.10% year-on-year[6] Revenue Decline Factors - The company noted that the decline in revenue was primarily due to decreased sales prices of its main formulation products[6]